Valuation: HLS Therapeutics Inc.

Market Cap 87.26M 77.93M 72.5M 65.94M 125M 8.45B 125M 873M 342M 4.31B 328M 321M 13.82B P/E 2026 *
-13.9x
P/E 2027 * -40.9x
Enterprise Value 87.26M 77.93M 72.5M 65.94M 125M 8.45B 125M 873M 342M 4.31B 328M 321M 13.82B EV / Sales 2026 *
1.5x
EV / Sales 2027 * 1.34x
Free-Float
99.45%
Yield 2026 *
-
Yield 2027 * -
1 day-2.62%
1 week+5.68%
Current month-2.62%
1 month+9.07%
3 months-4.44%
6 months-7.05%
Current year-15.15%
1 week 3.9
Extreme 3.9
4.43
1 month 3.7
Extreme 3.7
4.43
Current year 3.56
Extreme 3.56
5.25
1 year 3.56
Extreme 3.56
5.64
3 years 3
Extreme 3
5.76
5 years 3
Extreme 3
20.52
10 years 3
Extreme 3
25.92
Manager TitleAgeSince
Chief Executive Officer 58 30/04/2023
Director of Finance/CFO 61 25/01/2024
Chief Tech/Sci/R&D Officer 61 31/05/2014
Director TitleAgeSince
Director/Board Member 58 11/03/2018
Chairman 48 21/06/2023
Director/Board Member 65 31/12/2020
Date Insider Type Main position Quantity % Market Cap. Importance
08/09/26 Buy

Compliance Officer

2,000 0.0064%
01/09/26 Buy

Chief Financial Officer

2,000 0.0064%
28/08/26 TaxCompany -2,000 0.0064% -
Change 5-day change 1-year change 3-year change Capi.($)
-2.62%+5.68%-28.50%-17.04% 87.26M
+0.83%+3.19%+37.87%+106.25% 1,051B
+1.93%+2.11%+36.82%+64.90% 630B
+1.49%+5.19%+19.84%+85.41% 489B
+2.26%+0.90%+66.40%+39.33% 359B
+1.45%+3.50%+21.87%+42.64% 344B
+1.17%+2.37%+11.71%+35.14% 272B
+0.89%+1.08%-7.28%+10.52% 246B
+1.82%+2.94%+40.43%+52.78% 224B
+2.77%+4.44%+29.49%+101.40% 187B
Average +1.09%+2.85%+22.87%+52.13% 380.38B
Weighted average by Cap. +1.20%+2.44%+31.57%+69.96%

Financials

2026 *2027 *
Net sales 58.34M 52.1M 48.47M 44.09M 83.24M 5.65B 83.6M 583M 229M 2.88B 219M 214M 9.24B 65.06M 58.1M 54.05M 49.16M 92.83M 6.3B 93.23M 651M 255M 3.21B 244M 239M 10.3B
Net income -5.47M -4.88M -4.54M -4.13M -7.8M -529M -7.84M -54.69M -21.43M -270M -20.54M -20.09M -866M -2.16M -1.93M -1.8M -1.64M -3.09M -209M -3.1M -21.64M -8.48M -107M -8.13M -7.95M -343M
Net Debt - -
Projected Income Statement - Annual - HLS Therapeutics Inc.
Logo HLS Therapeutics Inc.
HLS Therapeutics Inc. is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. It is engaged in addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease. Its products include Clozaril, CSAN Pronto, MyCare Psychiatry and Vascepa. Its Clozaril is an atypical antipsychotic indicated for the management of symptoms of treatment-resistant schizophrenia for the Canadian and United States markets. CSAN Pronto is designed to enhance and simplify the mandatory safety blood monitoring process for patients that are prescribed Clozaril. Vascepa capsules are a single-molecule prescription product for the treatment of cardiovascular disease.
Employees
85
Date Price Change Volume
09/10/26 CA$4.090 -2.62% 142,079
08/10/26 CA$4.200 -1.18% 33,088
07/10/26 CA$4.250 +1.19% 20,388
06/10/26 CA$4.200 -0.24% 68,728
05/10/26 CA$4.210 +8.79% 437,761
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Ratings Surperformance© - HLS Therapeutics Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.866USD
Average target price
5.269USD
Spread / Average Target
+83.81%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - HLS Therapeutics Inc.